Tables
- TABLE 1
Demographic characteristics of subjects included in studies
Healthy individuals (n=40) Stable COPD (n=76) Acute exacerbations of COPD (n=61) p-value for group comparison Age years 61.6±12.0 69.3±10.2 71.5±11.1 0.70 Sex (females/males) 25/15 33/43 23/38 0.35 Body mass index (kg·m−2) 29.5±5.7 28.3±7.4 24.9±4.9 0.19 Smoking pack-years 8.6±13.6 41.1±25.6 59.1±51.9 0.027 Lung function FEV1 post-bronchodilator % pred 100.9±16.7 55.6±23.3 48.2±19.8 0.062 FEV1/FVC % 76.1±7.6 46.2±13.3 48.8±15.0 0.31 Bronchodilator response % 3.5±3.7 9.0±9.4 6.2±7.9 0.21 TLCO % pred 89.6±13.6 58.9±21.7 49.9±21.3 0.032 Inhaled treatment(s) Inhaled corticosteroids None 14 (18.4%) 43 (70%) <0.0001 Long-acting β-agonist None 59 (77.6%) 43 (70%) 0.43 Long-acting muscarinic antagonist None 58 (76.3%) 38 (62%) 0.09 Inspiratory vocal cord closure None 21 (27.6%) 19 (31.1%) 0.71 Expiratory vocal cord closure None 22 (28.9%) 17 (27.9%) 1.0 Values are presented as mean±sd or n (%), unless otherwise stated. p values from ANOVA, or Fisher's exact test as appropriate. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; TLCO: diffusing/transfer capacity for carbon monoxide.
Supplementary Materials
Supplementary Material
This one-page PDF can be shared freely online.
Shareable PDF ERJ-01466-2019.Shareable
Vol 55 Issue 5
Table of Contents
Inspiratory vocal cord closure in COPD
